System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Fabio L M Ricciardolo is an expert in Pulmonology at University of Turin (Italy). As of October 2026, ScienceLeadR ranks Fabio L M Ricciardolo in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Fabio L M Ricciardolo has authored 235 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 3 of them ongoing. SLR score: 908 (community average: 125). How the SLR is computed.

LeadR Profile

Fabio L M Ricciardolo University of Turin Italy
908 ScienceLeadR Reputation 908

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Immunology - Biochemistry - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1994 - 2026
Source: PubMed

University of Turin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 235

Citations

Citations: 7 851 1st author: 51 Last author: 73 Unique author: 6

Main journals

05.02 - Monitoring airway disease 25
Respir Med 8
Am J Respir Crit Care Med 7
Clin Exp Allergy 7
Eur J Pharmacol 7

Best Journals

Lancet 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Emerging therapeutic strategies and clinical trials in severe asthma management: current evidence and future directions.
PMID 42872730 — alarmins, biomarkers, precision medicine, therapeutics, asthma		Expert Opin Biol Ther20260
Exhaled nitric oxide measurement in patients with connective tissue diseases associated with interstitial lung disease: a narrative review.
PMID 42566045 — research design, sclerosis, lung, connective tissue, connective tissue diseases, biomarkers, lupus erythematosus, systemic, arthritis, rheumatoid, therapeutics, lung diseases, tissues, scleroderma, systemic, lung diseases, interstitial		Med Gas Res20260
Impact of Epigenetic Modifications in Airway Diseases. Role of Inflammation, Environmental Factors and Aging.
PMID 42503541 — genes, lung, respiration, aging, airway remodeling, air, pulmonary disease, chronic obstructive, therapeutics, lung diseases		Lung20260
Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Moderate-to-Severe Asthma, Type 2 Inflammation, and Nocturnal Awakenings: The MORPHEO Randomized Controlled Trial.
PMID 42370853 — hypersensitivity, sleep, immunity, asthma		J Investig Allergol Clin Immunol20260
Twelve-Month Real-World Outcomes of Tezepelumab in Severe Asthma: Clinical Remission, Biomarker Changes, and Trigger Burden-A SANI Multicenter Cohort.
PMID 42346632 — biomarkers, asthma, physical exertion		J Pers Med20260

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3
Phase 2 2
Phase 4 2
Phase 3 1

By status:

Completed 4
Recruiting 3
Active not recruiting 1

By type:

Interventional 6
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged 40 to 85 years with chronic obstructive pulmonary disease
2025-521268-37-00 — lung, respiratory tract diseases, aged, pulmonary disease, chronic obstructive, lung diseases, lung diseases, obstructive		Phase 4Recruiting2025
An open label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma
2024-512113-41-00 — maintenance, therapeutics, asthma		Phase 3Active not recruiting2024
A Study to Learn About the Study Medicine Called PF 07275315 in People With Moderate to Severe Asthma
2024-517866-40-00 — safety, asthma		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS